Medicine and Dentistry
Inflammatory Bowel Disease
100%
Crohn's Disease
49%
COVID-19
45%
Infliximab
42%
Ulcerative Colitis
41%
Diseases
38%
Severe Acute Respiratory Syndrome Coronavirus 2
25%
Infection
21%
Patient with Crohn's Disease
20%
Bifidobacterium
17%
Therapeutic Drug Monitoring
17%
Clinical Trial
17%
Biological Product
16%
Health Care Cost
16%
Irritable Bowel Syndrome
15%
Low FODMAP Diet
15%
Biosimilar
15%
T Cell
15%
Small Intestine
15%
Endoscopy
12%
Gut Microbiota
12%
Observational Study
10%
Maintenance Therapy
10%
Adalimumab
10%
Antibody Response
9%
Biopsy Technique
9%
Enzyme Linked Immunosorbent Assay
9%
Personalized Medicine
9%
Clinician
8%
Quality of Life
8%
Gene Expression
8%
Cohort Analysis
7%
Systematic Review
7%
Regulatory T Cell
7%
Checklist
7%
Granulomatosis
7%
Clinical Research
7%
Cardiogenic Shock
7%
Mental Health
7%
Convalescence
7%
Cohort Study
7%
Advanced Therapy
7%
Fecal Microbiota Transplantation
7%
Vedolizumab
7%
Tumor Necrosis Factor
7%
Prebiotics
7%
Butyrophilin
7%
Golimumab
7%
Immunogenicity
7%
Galactose Oligosaccharide
7%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
86%
Crohn's Disease
57%
Ulcerative Colitis
49%
Infliximab
36%
Remission
35%
Mercaptopurine
30%
Adalimumab
24%
Therapeutic Drug Monitoring
24%
Ustekinumab
23%
Diseases
22%
Biological Product
21%
Colitis
16%
SARS Coronavirus
16%
Enzyme-Linked Immunosorbent Assay
15%
Feces microflora
15%
COVID-19 Vaccine
15%
Case-Control Study
15%
Tofacitinib
14%
Drug Concentration
14%
Tumor Necrosis Factor
13%
Immunogenicity
11%
Pandemic
10%
Clinical Trial
10%
Inflammation
9%
Janus Kinase Inhibitor
9%
Calgranulin
9%
Cohort Study
8%
Disease Activity
8%
Infection
7%
Adult Respiratory Distress Syndrome
7%
Intestine Flora
7%
Campylobacter Enteritis
7%
Granulomatosis
7%
Golimumab
7%
Vasoactive Intestinal Polypeptide
7%
Ileitis
7%
Biosimilar Agent
7%
Tioguanine
7%
Clinical Research
7%
Clostridium Difficile Infection
7%
Galactose Oligosaccharide
7%
Monotherapy
7%
Tumor Necrosis Factor Inhibitor
7%
Drug Antibody
6%
Immunomodulating Agent
5%
Gastrointestinal Symptom
5%
Common Variable Immunodeficiency
5%
Adverse Event
5%
Immunology and Microbiology
Inflammatory Bowel Disease
70%
Infliximab
68%
Severe Acute Respiratory Syndrome Coronavirus 2
47%
Crohn's Disease
33%
Antibody Response
32%
COVID-19
30%
T Cell
24%
Vedolizumab
23%
Adalimumab
22%
Regulatory T Cell
20%
Adoptive Immunity
15%
Biosimilar Agent
15%
Feces microflora
15%
Drug Concentration
15%
Antibody Blood Level
12%
Tofacitinib
10%
Breakthrough Infection
9%
Wild Type
8%
Immunogenicity
8%
Ulcerative Colitis
8%
Immunoglobulin E
7%
Autoimmunity
7%
Omicron Coronavirus Variant
7%
Neutralizing Antibody
7%
Virus Type
7%
Golimumab
7%
Campylobacter Jejuni
7%
Enhancer Region
7%
Blood Level
7%
Integrin
7%
Interleukin 2
7%
Peptoclostridium difficile
7%
Cell Selection
7%
Spike
7%
Tumor Necrosis Factor Alpha
6%
Ustekinumab
5%
Enzyme-Linked Immunosorbent Assay
5%
Common Variable Immunodeficiency
5%